{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:51:58Z","timestamp":1781632318994,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Institutional Natural Science Foundation","award":["WK2023ZQNZ56"],"award-info":[{"award-number":["WK2023ZQNZ56"]}]},{"name":"Anhui Province Quality Engineering Research Project","award":["2023jyxm1238"],"award-info":[{"award-number":["2023jyxm1238"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transcatheter aortic valve implantation (TAVI) is a standard minimally invasive treatment for high-risk patients with severe aortic valve disease. However, the safety of permanent pacemaker implantation (PPI) following TAVI under multiple antithrombotic regimens remains inadequately studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center retrospective study, 203 patients who underwent TAVI between January 2021 and May 2025 were included. Based on post-TAVI PPI status, patients were categorized into pacemaker (PM,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935) and non-pacemaker (NPM,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009168) groups. Each group was further stratified by antithrombotic regimen (mono-[MA], dual-[DA], or triple-antithrombotic [TA] therapy). Outcomes, including pocket hematoma, thromboembolic events, and infections, were assessed over a three-month follow-up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No significant differences in baseline characteristics were observed between the PM and NPM groups. In the PM group, one death occurred in the TA subgroup. Pocket hematoma and major bleeding each occurred in one patient in the TA subgroup, and lead dislodgement occurred in one patient in the DA subgroup. No significant differences in complication rates were found among antithrombotic subgroups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). The use of optimized hemostatic techniques\u2014including electrocautery, hemostatic sponges, and compressive bandaging\u2014was associated with low overall hematoma and infection rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PPI following TAVI appears safe under various antithrombotic therapies when accompanied by meticulous hemostatic management. Individualized antithrombotic strategies and standardized perioperative techniques may mitigate bleeding and thrombotic risks in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05528-y","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:44:43Z","timestamp":1768992283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety study of permanent pacemaker implantation after TAVI under multiple antithrombotic therapies"],"prefix":"10.1186","volume":"26","author":[{"given":"Yu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"24","key":"5528_CR1","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1161\/01.CIR.0000047200.36165.B8","volume":"106","author":"A Cribier","year":"2002","unstructured":"Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006\u20138.","journal-title":"Circulation"},{"issue":"17","key":"5528_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","volume":"374","author":"MB Leon","year":"2016","unstructured":"Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical Aortic-Valve replacement in Intermediate-Risk patients. N Engl J Med. 2016;374(17):1609\u201320.","journal-title":"N Engl J Med"},{"issue":"16","key":"5528_CR3","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.jcin.2023.07.026","volume":"16","author":"E De Poletti","year":"2023","unstructured":"Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON international project. JACC Cardiovasc Interv. 2023;16(16):1974\u201385.","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"5528_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jacc.2013.01.018","volume":"61","author":"DA Roy","year":"2013","unstructured":"Roy DA, Schaefer U, Guetta V, Hildick-Smith D, Mollmann H, Dumonteil N, et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 2013;61(15):1577\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"5528_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2022.05.002","volume":"101","author":"DJ van Ginkel","year":"2022","unstructured":"van Ginkel DJ, Bor WL, Veenstra L, van \u2018t Hof AWJ, Fabris E. Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Eur J Intern Med. 2022;101:14\u201320.","journal-title":"Eur J Intern Med"},{"key":"5528_CR6","doi-asserted-by":"publisher","unstructured":"Vistisen H, Graversen PL, Havers-Borgersen E, Strange JE, \u00d8stergaard L, Butt JH, et al. Antithrombotic therapy following transcatheter aortic valve implantation: a Danish nationwide study. Eur Heart J Qual Care Clin Outcomes. 2025;11(5):604-13. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf003.","DOI":"10.1093\/ehjqcco\/qcaf003"},{"issue":"5","key":"5528_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/ehjcvp\/pvad101","volume":"10","author":"RD Turgeon","year":"2024","unstructured":"Turgeon RD, Ellis UM, Barry AR. Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2024;10(5):454\u201364.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"5528_CR8","doi-asserted-by":"publisher","unstructured":"Moreno R, Souza J, Smolnik R, Nombela-Franco L, Van Mieghem NM, Hengstenberg C, et al. Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: results from the ENVISAGE-TAVI AF trial. Clin Res Cardiol. 2025;114(3):313-22. https:\/\/doi.org\/10.1007\/s00392-024-02379-5.","DOI":"10.1007\/s00392-024-02379-5"},{"issue":"4","key":"5528_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11239-013-0886-z","volume":"35","author":"DR Lynch Jr","year":"2013","unstructured":"Lynch DR Jr., Dantzler D, Robbins M, Zhao D. Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis. 2013;35(4):476\u201382.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"5528_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ancard.2019.09.020","volume":"68","author":"P Guedeney","year":"2019","unstructured":"Guedeney P, Collet JP. [What antithrombotic treatment should we prescribe after transvalvular aortic valve implantation?]. Ann Cardiol Angeiol (Paris). 2019;68(6):462\u20137.","journal-title":"Ann Cardiol Angeiol (Paris)"},{"issue":"11","key":"5528_CR11","first-page":"679","volume":"17","author":"A Robson","year":"2020","unstructured":"Robson A. Aspirin alone is safer than dual antiplatelet therapy in patients undergoing TAVI. Nat Rev Cardiol. 2020;17(11):679.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"5528_CR12","doi-asserted-by":"publisher","first-page":"e010097","DOI":"10.1161\/CIRCINTERVENTIONS.120.010097","volume":"14","author":"Y Kobari","year":"2021","unstructured":"Kobari Y, Inohara T, Saito T, Yoshijima N, Tanaka M, Tsuruta H, et al. Aspirin versus clopidogrel as single antithrombotic therapy after transcatheter aortic valve replacement: insight from the OCEAN-TAVI registry. Circ Cardiovasc Interv. 2021;14(5):e010097.","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"5528_CR13","doi-asserted-by":"publisher","first-page":"26543","DOI":"10.31083\/RCM26543","volume":"26","author":"C Ju","year":"2025","unstructured":"Ju C, Zhou Y, Ge T, Tang S, Guo Z, Cao S. Outcomes of permanent pacemaker implantation in patients with pure aortic regurgitation after TAVI. Rev Cardiovasc Med. 2025;26(5):26543.","journal-title":"Rev Cardiovasc Med"},{"key":"5528_CR14","doi-asserted-by":"publisher","unstructured":"Ju C, Xie X, Tang S, Cao S. Predictors of permanent pacemaker implantation in aortic valve diseases after TAVI with VitaFlow liberty system. Front Cardiovasc Med. 2023;(29)10:1277528. https:\/\/doi.org\/10.3389\/fcvm.2023.1277528.","DOI":"10.3389\/fcvm.2023.1277528"},{"issue":"1","key":"5528_CR15","first-page":"Cd013816","volume":"1","author":"B Chen","year":"2025","unstructured":"Chen B, Phan M, Pasupuleti V, Roman YM, Hernandez AV. Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion. Cochrane Database Syst Rev. 2025;1(1):Cd013816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"5528_CR16","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","volume":"42","author":"J Van Ten Berg","year":"2021","unstructured":"Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC working group on thrombosis and the European association of percutaneous cardiovascular interventions (EAPCI), in collaboration with the ESC Council on valvular heart disease. Eur Heart J. 2021;42(23):2265\u20139.","journal-title":"Eur Heart J"},{"issue":"18","key":"5528_CR17","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.jcin.2023.08.011","volume":"16","author":"A Franzone","year":"2023","unstructured":"Franzone A. G <>Esposito 2023 VARC-3 criteria for bleeding events: integrating theory into practice. JACC Cardiovasc Interv 16 18 2275\u20136.","journal-title":"JACC Cardiovasc Interv"},{"key":"5528_CR18","doi-asserted-by":"publisher","unstructured":"Kille A, Franke K, Corpataux N, Hromek J, Valina CM, Neumann FJ, et al. Impact of On-Clopidogrel platelet reactivity on incidence of Peri-Interventional bleeding in patients undergoing transcatheter aortic valve implantation. J Clin Med. 2022;11(10) :2871. https:\/\/doi.org\/10.3390\/jcm11102871.","DOI":"10.3390\/jcm11102871"},{"issue":"2","key":"5528_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10557-021-07146-6","volume":"36","author":"M Alkhalil","year":"2022","unstructured":"Alkhalil M, Edwards R, Puri R, Kalra A, Zaman A, Das R. Aspirin versus dual antiplatelet therapy in patients undergoing Trans-Catheter aortic valve Implantation, updated Meta-Analysis. Cardiovasc Drugs Ther. 2022;36(2):279\u201383.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"5528_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","volume":"383","author":"J Brouwer","year":"2020","unstructured":"Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Aspirin with or without clopidogrel after transcatheter Aortic-Valve implantation. N Engl J Med. 2020;383(15):1447\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"5528_CR21","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/clc.23731","volume":"44","author":"S Yu","year":"2021","unstructured":"Yu S, Zhang S, Yao C, Liu J. Effects of single versus dual antiplatelet therapy on the adverse events after transcatheter aortic valve implantation: A meta-analysis. Clin Cardiol. 2021;44(12):1718\u201328.","journal-title":"Clin Cardiol"},{"issue":"2","key":"5528_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10557-021-07145-7","volume":"36","author":"X Lin","year":"2022","unstructured":"Lin X, Wang S, Wang L, Guan Y, Huang J. Aspirin alone versus dual antiplatelet therapy after transcatheter aortic valve replacement: A systematic review and Meta-Analysis. Cardiovasc Drugs Ther. 2022;36(2):271\u20138.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"5528_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ehjcvp\/pvz064","volume":"7","author":"JH Butt","year":"2021","unstructured":"Butt JH, De Backer O, Olesen JB, Gerds TA, Havers-Borgersen E, Gislason GH, et al. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021;7(1):11\u20139.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"22","key":"5528_CR24","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jcin.2020.09.013","volume":"13","author":"H Kawashima","year":"2020","unstructured":"Kawashima H, Watanabe Y, Hioki H, Kozuma K, Kataoka A, Nakashima M, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv. 2020;13(22):2587\u201397.","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"5528_CR25","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","volume":"14","author":"R Didier","year":"2021","unstructured":"Didier R, Lhermusier T, Auffret V, Eltchaninoff H, Le Breton H, Cayla G, et al. TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist? JACC cardiovasc interv. 2021;14(15):1704\u201313.","journal-title":"JACC cardiovasc interv"},{"key":"5528_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.amjcard.2023.06.049","volume":"201","author":"V Selvaraj","year":"2023","unstructured":"Selvaraj V, Khan MS, Mufarrih SH, Kazimuddin M, Waheed MA, Tripathi A, et al. Meta-Analysis assessing efficacy and safety of vitamin K antagonists versus direct oral anticoagulants for atrial fibrillation after transcatheter aortic valve implantation. Am J Cardiol. 2023;201:260\u20137.","journal-title":"Am J Cardiol"},{"issue":"1","key":"5528_CR27","doi-asserted-by":"publisher","first-page":"e023561","DOI":"10.1161\/JAHA.121.023561","volume":"11","author":"T Tanawuttiwat","year":"2022","unstructured":"Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT registry. J Am Heart Assoc. 2022;11(1):e023561.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"5528_CR28","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","volume":"382","author":"VJ Nijenhuis","year":"2020","unstructured":"Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Anticoagulation with or without clopidogrel after transcatheter Aortic-Valve implantation. N Engl J Med. 2020;382(18):1696\u2013707.","journal-title":"N Engl J Med"},{"issue":"5","key":"5528_CR29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10557-020-07081-y","volume":"35","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Meng S, Chen M, Jia R, Nan J, Li H, et al. Comparing anticoagulation therapy alone versus anticoagulation plus single antiplatelet drug therapy after transcatheter aortic valve implantation in patients with an indication for anticoagulation: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2021;35(5):995\u20131002.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"5528_CR30","first-page":"132","volume":"50","author":"SC Zhou","year":"2022","unstructured":"Zhou SC, Xu K, Wang B, Wang G, Liang ZY, Li Y, et al. [One-year follow-up results of atrial fibrillation patients who undergoing transcatheter aortic valve implantation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022;50(2):132\u20136.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"3","key":"5528_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ehjcvp\/pvad003","volume":"9","author":"P Guedeney","year":"2023","unstructured":"Guedeney P, Roule V, Mesnier J, Chapelle C, Portal JJ, Laporte S, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(3):251\u201361.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"5528_CR32","doi-asserted-by":"publisher","first-page":"e13589","DOI":"10.1111\/eci.13589","volume":"51","author":"M Mach","year":"2021","unstructured":"Mach M, Watzal V, Cuhaj C, Hasan W, Poschner T, Szalkiewicz P, et al. The impact of antiplatelet and antithrombotic regimen after TAVI: data from the VIenna cardiothoracic aortic valve registry (VICTORY). Eur J Clin Invest. 2021;51(9):e13589.","journal-title":"Eur J Clin Invest"},{"key":"5528_CR33","doi-asserted-by":"publisher","unstructured":"Lind A, Ahsan M, Kaya E, Wakili R, Rassaf T, J\u00e1nosi RA. Early pacemaker implantation after transcatheter aortic valve replacement: impact of PlasmaBlade\u2122 for prevention of Device-Associated bleeding complications. Med (Kaunas). 2021;57(12):1331. https:\/\/doi.org\/10.3390\/medicina57121331.","DOI":"10.3390\/medicina57121331"},{"issue":"3","key":"5528_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10840-018-0488-y","volume":"54","author":"H Awada","year":"2019","unstructured":"Awada H, Geller JC, Brunelli M, Ohlow MA. Pocket related complications following cardiac electronic device implantation in patients receiving anticoagulation and\/or dual antiplatelet therapy: prospective evaluation of different preventive strategies. J Interv Card Electrophysiol. 2019;54(3):247\u201355.","journal-title":"J Interv Card Electrophysiol"},{"issue":"3","key":"5528_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00380-016-0879-x","volume":"32","author":"K Ishibashi","year":"2017","unstructured":"Ishibashi K, Miyamoto K, Kamakura T, Wada M, Nakajima I, Inoue Y, et al. Risk factors associated with bleeding after multi antithrombotic therapy during implantation of cardiac implantable electronic devices. Heart Vessels. 2017;32(3):333\u201340.","journal-title":"Heart Vessels"},{"issue":"10","key":"5528_CR36","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/00015385.2022.2119660","volume":"77","author":"D Angellotti","year":"2022","unstructured":"Angellotti D, Manzo R, Castiello DS, Piccolo R, Avvedimento M, Leone A, et al. Impact of COVID-19 pandemic on timing and early clinical outcomes of transcatheter aortic valve implantation. Acta Cardiol. 2022;77(10):937\u201342.","journal-title":"Acta Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05528-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:54:40Z","timestamp":1781628880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05528-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5528"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05528-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7957715\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of The First Affiliated Hospital of Wannan Medical College (Approval Number: [2024]23). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}